1492 Capital Management’s Charles River Laboratories CRL Stock Holding History

1492 Capital Management’s Portfolio CRL Stock Details CRL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$1.36M	Buy	7,875 +1,816	+30%	+$337K	0.52%	58
2025 Q4	$1.21M	Buy	+6,059	New	+$1.1M	0.46%	61
2022 Q3	–	Sell	-5,738	Closed	-$1.23M	–	109
2022 Q2	$1.23M	Buy	5,738 +10	+0.2%	+$2.44K	0.81%	42
2022 Q1	$1.63M	Sell	5,728 -69	-1%	-$21.3K	0.86%	41
2021 Q4	$2.18M	Hold	5,797	–	–	1.08%	33
2021 Q3	$2.39M	Sell	5,797 -78	-1%	-$32.4K	1.21%	29
2021 Q2	$2.17M	Hold	5,875	–	–	1.11%	33
2021 Q1	$1.7M	Sell	5,875 -153	-3%	-$42.5K	0.97%	41
2020 Q4	$1.51M	Buy	6,028 +473	+9%	+$113K	0.87%	38
2020 Q3	$1.26M	Buy	5,555 +329	+6%	+$68.3K	0.94%	35
2020 Q2	$911K	Sell	5,226 -35	-0.7%	-$5.59K	0.78%	39
2020 Q1	$664K	Sell	5,261 -10	-0.2%	-$1.5K	0.79%	41
2019 Q4	$805K	Sell	5,271 -18	-0.3%	-$2.49K	0.71%	40
2019 Q3	$700K	Sell	5,289 -187	-3%	-$25.1K	0.68%	46
2019 Q2	$777K	Sell	5,476 -85	-2%	-$11.5K	0.73%	45
2019 Q1	$808K	Sell	5,561 -552	-9%	-$72.5K	0.68%	47
2018 Q4	$692K	Sell	6,113 -438	-7%	-$54.8K	0.62%	50
2018 Q3	$881K	Buy	6,551 +588	+10%	+$72.6K	0.57%	54
2018 Q2	$669K	Buy	+5,963	New	+$645K	0.48%	65
2015 Q4	–	Sell	-11,211	Closed	-$712K	–	120
2015 Q3	$712K	Buy	11,211 +4,409	+65%	+$317K	0.51%	50
2015 Q2	$478K	Sell	6,802 -6,825	-50%	-$505K	0.3%	81
2015 Q1	$1.08M	Sell	13,627 -1,109	-8%	-$81.8K	0.63%	37
2014 Q4	$938K	Buy	14,736 +3,994	+37%	+$250K	0.59%	53
2014 Q3	$642K	Buy	+10,742	New	+$615K	0.36%	68

Other funds holding CRL

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Harris Associates Chicago, Illinois $75B AUM 11.27% 1-Year Est. Return

Allspring Global Investments Charlotte, North Carolina $59.7B AUM 29.08% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

1492 Capital Management's CRL Position: Q1 2026 in Review

1492 Capital Management increased its Charles River Laboratories (CRL) stake by 30% in Q1 2026, buying an estimated $337K and bringing the position to 7,875 shares worth $1.36M. The position accounts for 0.52% of the portfolio, ranked #58.

1492 Capital Management first reported a position in CRL in Q3 2014 and has held it in 24 quarters since. The position peaked at $2.39M in Q3 2021. 557 funds tracked by Wall St. Rank hold CRL as of Q1 2026.

1492 Capital Management held 7,875 shares of Charles River Laboratories worth $1.36M as of Q1 2026.
1492 Capital Management bought 1,816 Charles River Laboratories shares in Q1 2026, an estimated $337K.
Charles River Laboratories made up 0.52% of 1492 Capital Management's portfolio in Q1 2026, its #58 holding.
1492 Capital Management first reported a position in Charles River Laboratories in Q3 2014 and has held it in 24 quarters since.
1492 Capital Management's Charles River Laboratories position peaked at $2.39M in Q3 2021.
557 funds tracked by Wall St. Rank held Charles River Laboratories as of Q1 2026.

Based on 1492 Capital Management's 13F filing for Q1 2026, filed 22 Apr 2026.